It is currently Fri Sep 04, 2015 12:58 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

FTY720

FTY720 is seen by some as being the 'gold standard' for MS treatment in the future. Unfortunately, approval unlikely until 2010.

In recognition of my sterling efforts this week Arron has kindly offered me two free weeks at his villa in California. Many thanks Arron I'll keep the good work up.

Ian



Novartis: FTY720 offers gold standard MS potential 16 March 2006

Novartis drug to become preferred front-line agent for the treatment of multiple sclerosis. ...
Read more : FTY720 | Views : 2009 | Replies : 4


Overview of drugs

Nothing new but a summary of what's available / in the pipeline.

http://c.moreover.com/click/here.pl?j486543664&w=464753
Read more : Overview of drugs | Views : 1454 | Replies : 0


exosomes

Dignan,

Probably shouldn't go on the list as its only a possibility that it might be beneficial for MS.


http://c.moreover.com/click/here.pl?j486821238&w=464753
Read more : exosomes | Views : 1265 | Replies : 1


MBP8298 For RRMS

BioMS Plans Relapsing-Remitting Multiple Sclerosis Trial

- MBP8298 to be tested in a second major MS patient population -

EDMONTON, Alberta, March 13, 2006 – BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it is expanding the clinical development program for its lead drug candidate MBP8298. The drug is currently undergoing an international pivotal phase II/III clinical trial with secondary progressive MS patients (SPMS). BioMS ...
Read more : MBP8298 For RRMS | Views : 1410 | Replies : 1


Gemacbio

I think the following is old news. Unfortunately, no details about how effective the treatment is - but I like the three pronged approach. It's very safe (but so is eating spinach)!

http://c.moreover.com/click/here.pl?j485748659&w=464753
Read more : Gemacbio | Views : 1223 | Replies : 0


Tovaxin Update/Trial

This from BBC news.


MS vaccine testing to start in US

Researchers are working towards having an MS vaccine
A US company is set to begin a trial of a vaccine which it claims halts the progress of multiple sclerosis.

PharmaFrontiers is to test its tailor-made vaccine on 100 patients with MS, after a small-scale study showed promise, New Scientist reports.

MS experts have welcomed the research but urged caution because other vaccines have not ...
Read more : Tovaxin Update/Trial | Views : 1679 | Replies : 3


The pharma industry

I read postings on this forum on a regular basis and quite often it amases me. We all have an awful disease and it is a rough ride. But i think we are very quick to judge..

common themes include

Anti - CRABS (well I'm on copaxone and doing great - I know its not for everyone, but I cant be the only one who is doing well on it? OK so its not a ...
Read more : The pharma industry | Views : 2637 | Replies : 12


Generic interferons

Not that anybody is excited about interferons, but if they must be taken at least they might be about to get cheaper...



Ratiopharm: competes with Stada, Sandoz on biogeneric drugs

Mar 8, 2006 - Marketwatch - German generic drug maker Ratiopharm GmbH Wednesday said it is competing with German generics company Stada AG and Novartis AG's generic subsidiary Sandoz in the race for biogeneric drugs to be approved in Europe.

Although the company, which had ...
Read more : Generic interferons | Views : 1372 | Replies : 0


Neurocrine APL

Dignan,

If this was on the list you need to erase it.

Ian

http://c.moreover.com/click/here.pl?j482124809&w=464753
Read more : Neurocrine APL | Views : 1368 | Replies : 1


MBP8298 update

This sounds promising, although they don't provide much information here...



BioMS Medical's MBP8298 Shows Five-year Delay of Disease Progression in Patients with Multiple Sclerosis

March 7, 2006- BioMS Medical today announced that its proprietary drug candidate MBP8298 delayed disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.

Treatment and follow-up of patients from a phase II clinical study demonstrated that patients in this DR2 and DR4 responder group, ...
Read more : MBP8298 update | Views : 1323 | Replies : 1


 

Login  •  Register


Statistics

Total posts 227135 • Total topics 23950 • Total members 15296


Contact us | Terms of Service